The RI-MUHC scientist will join 55 experts from more than 30 countries working jointly to study fatty liver and cardiovascular disease
Dr. Giada Sebastiani will participate in the International Delphi Consensus on Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Cardiovascular Disease.
“We know that over 25% of adults worldwide are affected by metabolic dysfunction-associated fatty liver disease and that cardiovascular disease is the leading cause of death in patients with fatty liver disease,” says Dr. Sebastiani, a scientist in the Infectious Diseases and Immunity in Global Health Program at the Research Institute of the McGill University Health Centre. “However, in order to improve patient care, more attention needs to be brought to the associations between fatty liver disease and cardiovascular disease.”
Commissioned by the high-impact journal Nature Reviews Cardiology, this international panel of 55 experts from more than 30 countries will work to determine the relationship between fatty liver disease and cardiovascular disease and will provide recommendations for clinical practice in hepatology, cardiology, and endocrinology. This work follows the publication in October 2021 of a consensus statement by a multidisciplinary group of experts. It is part of a global effort to increase awareness of the impacts of fatty liver disease, and to develop comprehensive public health responses. Dr. Sebastiani assumed her role on the panel at the end of August 2022.
An associate professor in the Department of Medicine at McGill University, Dr. Sebastiani’s work has made her a leading expert in the epidemiology, natural history and extra-hepatic complications of fatty liver disease. Congratulations Dr. Sebastiani on this prestigious invitation!